Letter to the editorPrevalence of metabolic syndrome in Japanese psoriasis patients
References (10)
- et al.
Nonalcoholic fatty liver, steatohepatitis, and metabolic syndrome
Hepatology
(2003) - et al.
Prevalence of obesity/adiposity in Japanese psoriasis patients: adiposity is correlated with the severity of psoriasis
J Dermatol Sci
(2009) - et al.
Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients
Atherosclerosis
(2007) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
Circulation
(2002)- et al.
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study
Br J Dermatol
(2007)
Cited by (51)
Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome
2017, Journal of the American Academy of DermatologyCitation Excerpt :In the main outcome meta-analysis, Middle Eastern patients with psoriasis exhibited a greater risk for MS compared with Europeans. These results are similar to those presented by Armstrong et al.7 The literature is consistent with our results, demonstrating that the Middle Eastern general population has an increased prevalence of MS (approximately 40%).35 European cohorts exhibit a prevalence near 25%.80
Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report
2016, CytokineCitation Excerpt :Psoriasis is not only limited to skin manifestations or Quality of Life (QOL) impairment for patients, but an association has also been proven between this condition and MS components, primarily in terms of abdominal obesity, hypertriglyceridemia, and low levels of High-Density-Lipoprotein-cholesterol (HDL-c) [31–35]. In addition to causing keratinocyte hyperproliferation and increased angiogenesis in these patients, Th1/Th17 profile alterations are known to share pathophysiological pathways derived from Th1-mediated chronic inflammation with CardioVascular Diseases (CVD) including obesity, diabetes, hyperlipidemia, atherosclerosis, and MS [34,36–43]. Our results support this close relationship.
Prevalence of metabolic syndrome as per the NCEP and IDF definitions vis-a-vis severity and duration of psoriasis in a semi-urban Maharashtrian population: A case control study
2016, Diabetes and Metabolic Syndrome: Clinical Research and ReviewsCitation Excerpt :Low HDL was the most common (though not the most significant) component of MS associated with our psoriatics (70%), significantly higher than controls (48%, P = 0.002). A higher prevalence of low HDL levels in psoriatics has been reported by Takahashi et al. [22], whereas Nisa and Quazi [9] demonstrated its higher prevalence in controls. We observed similar HDL levels in cases and controls, in contrast to Pietrzak et al. [23] who found significantly decreased high-density lipoprotein (HDL)-cholesterol concentration (P < 0.001) in cases.
Serum Neprilysin Is a Significant Predictor of Metabolic Syndrome in Psoriasis Patients
2023, The Egyptian Journal of Hospital MedicineEffects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis
2023, Journal of Clinical Medicine